We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Second Lafora Disease Gene Identified

By Biotechdaily staff writers
Posted on 07 Oct 2003
Researchers have identified a second gene that causes Lafora disease (LD), the most severe form of teenage-onset epilepsy, and now explains the genetic basis for the disease in more than 90% of families with an afflicted child.

Lafora disease is a form of progressive myoclonus epilepsy beginning from age six to 19; characterized by generalized tonic-clonic seizures, resting and action myoclonus, ataxia, dementia, and classic EEG findings, including polyspike and wave discharges; basophilic cytoplasmic inclusion bodies present in portions of the brain, the liver, and skin, as well as the duct cells of the sweat glands. More...
Death usually occurs within 10 years of onset. Lafora disease is passed by autosomal recessive inheritance.

In a study published in the September 2003 issue of Nature Genetics, investigators from the University of Toronto (Canada; www.utoronto.ca) reported the discovery of the NHLRC1 gene, which is the second gene found to cause Lafora disease. The other gene, EPM2A, was discovered five years ago.

"The newly discovered LD gene, named NHLRC1, produces a protein thought to be involved in marking other proteins for destruction in the cell. Our early data suggest that the EPM2A and NHLRC1 genes work together to safeguard neurons against accumulating too many carbohydrates. If either of the genes is missing, the result is epilepsy,” explained senior author Dr. Stephen Scherer, associate professor of molecular and medical genetics at the University of Toronto. "Importantly, we can now explain Lafora disease in 90% of families, and for the remaining 10%, we think there is a third yet-to-be-identified disease gene.”




Related Links:
University of Toronto

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Pipette Calibration System
Artel PCS®
New
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Photo courtesy of Adobe Stock

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.